326 related articles for article (PubMed ID: 29210835)
41. Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol.
Jin X; Wang H; Li H; Chu Z; Zhang J; Hu Q; Lv W; Huang X; Chen Y; Wang H; He X; Zhang L; Hu Z; Bao R; Li S; Ding H; Geng W; Jiang Y; Shang H; Xu J;
BMC Public Health; 2020 Jul; 20(1):1160. PubMed ID: 32709230
[TBL] [Abstract][Full Text] [Related]
42. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.
Mugwanya KK; John-Stewart G; Baeten J
Expert Opin Drug Saf; 2017 Jul; 16(7):867-871. PubMed ID: 28571500
[TBL] [Abstract][Full Text] [Related]
43. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
[TBL] [Abstract][Full Text] [Related]
44. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
[TBL] [Abstract][Full Text] [Related]
45. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
[TBL] [Abstract][Full Text] [Related]
46. Evaluating statewide HIV preexposure prophylaxis implementation using All-Payer Claims Data.
Raifman J; Nocka K; Galárraga O; Wilson IB; Crowley C; Tao J; Napoleon S; Marak T; Chan PA
Ann Epidemiol; 2020 Apr; 44():1-7.e2. PubMed ID: 32279914
[TBL] [Abstract][Full Text] [Related]
47. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
Marins LMS; Torres TS; Leite IDC; Moreira RI; Luz PM; Hoagland B; Kallas EG; Madruga JV; Liu AY; Anderson PL; Grinsztejn B; Veloso VG
PLoS One; 2019; 14(8):e0221281. PubMed ID: 31430318
[TBL] [Abstract][Full Text] [Related]
48. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Krakower DS; Mayer KH
Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
[TBL] [Abstract][Full Text] [Related]
49. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
Mugwanya KK; Baeten JM
Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
[TBL] [Abstract][Full Text] [Related]
50. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA;
AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753
[TBL] [Abstract][Full Text] [Related]
51. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.
Solomon MM; Schechter M; Liu AY; McMahan VM; Guanira JV; Hance RJ; Chariyalertsak S; Mayer KH; Grant RM;
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):281-6. PubMed ID: 26413853
[TBL] [Abstract][Full Text] [Related]
52. Nondaily preexposure prophylaxis for HIV prevention.
Anderson PL; García-Lerma JG; Heneine W
Curr Opin HIV AIDS; 2016 Jan; 11(1):94-101. PubMed ID: 26633641
[TBL] [Abstract][Full Text] [Related]
53. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
Trang TP; Dong BJ; Kojima N; Klausner JD
Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
[TBL] [Abstract][Full Text] [Related]
54. Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT.
Velloza J; Bacchetti P; Hendrix CW; Murnane P; Hughes JP; Li M; Curlin ME; Holtz TH; Mannheimer S; Marzinke MA; Amico KR; Liu A; Piwowar-Manning E; Eshleman SH; Dye BJ; Gandhi M; Grant RM;
J Acquir Immune Defic Syndr; 2019 Oct; 82(2):149-158. PubMed ID: 31335588
[TBL] [Abstract][Full Text] [Related]
55. HIV Pre-Exposure Prophylaxis Medication for Adolescents and Young Adults: A Position Paper of the Society for Adolescent Health and Medicine.
Society for Adolescent Health and Medicine
J Adolesc Health; 2018 Oct; 63(4):513-516. PubMed ID: 30286903
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of Algorithms Used for PrEP Surveillance Using a Reference Population From New York City, July 2016-June 2018.
Furukawa NW; Smith DK; Gonzalez CJ; Huang YA; Hanna DB; Felsen UR; Zhu W; Arnsten JH; Patel VV
Public Health Rep; 2020; 135(2):202-210. PubMed ID: 32027559
[TBL] [Abstract][Full Text] [Related]
57. Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010-2014.
Wu H; Mendoza MC; Huang YA; Hayes T; Smith DK; Hoover KW
Clin Infect Dis; 2017 Jan; 64(2):144-149. PubMed ID: 27986691
[TBL] [Abstract][Full Text] [Related]
58. Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
Mugo PM; Sanders EJ; Mutua G; van der Elst E; Anzala O; Barin B; Bangsberg DR; Priddy FH; Haberer JE
AIDS Behav; 2015 May; 19(5):794-801. PubMed ID: 25432877
[TBL] [Abstract][Full Text] [Related]
59. HIV Prevention: Opportunities and Challenges.
Marrazzo JM
Top Antivir Med; 2017; 24(4):123-126. PubMed ID: 28208119
[TBL] [Abstract][Full Text] [Related]
60. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
